Charles Bishop, the CEO of the renal division ( Rayaldee ) stated on the earnings call that Opko could reach the MAJORITY of Drs. with a small sales force. So they will not likely partner. n his words:
Primarily nephrologists and endocrinologists care for these patients and they can be effectively reached with a small specialized sales force.
Given that there are at least 4 million patients with SHPT derived from vitamin D therapy or about 4 million to 4.5 million patients, if we were to price Rayaldee at the lower cost range of vitamin D therapy, which is $3,000 per year, the U.S. CKD market alone represents a potential $12 billion revenue opportunity.
So in summary, our early qualitative research with nephrologists and endos has shown that there's a clear unmet need for a product that could simultaneously correct both vitamin D insufficiency and SHPT, and with a high degree of interest in trying Rayaldee once it's approved.
Now in addition to the research with clinicians that I've just outlined, I can tell you that we also recently initiated research with both payors and patients and we expect to have something to share with you with regards to those findings on a future call.
Bottom line is OTC D works for some patients, but less than half, the generics highly touted by LW actually increase Vitamin D insufficiency but do lower shpt some times too much.
Rayaldee is a single drug and corrects both.
bust - I would just copy and paste part of Burn's post and ask her what she thinks? I'd be curious to hear feedback if you do!
Would be curious to hear her professional opinion on these statements:
"there's a clear unmet need for a product that could simultaneously correct both vitamin D insufficiency and SHPT, and with a high degree of interest in trying Rayaldee once it's approved.
Bottom line is OTC D works for some patients, but less than half, the generics highly touted by LW actually increase Vitamin D insufficiency but do lower shpt some times too much."
Thanks, burnaka (and miamianne67 for the TTT). Phase 4 data will further support the exceptional value of Rayaldee. Frost doesn't develop "me too" products but rather focuses on those that add true healthcare value. The effective use of a less expensive small sales force is another reflection of the good business practices used in all the projects undertaken by the Frost TEAM of entrepreneurs. Thanks again for posting this hidden update.
I almost missed this as I have been exceptionally busy. Burnaka thanks are not enough for what you bring to this Board. Instead of the endless chatter of day traders about day to day prices, you bring insight into the pipeline side that I know all serious investors here appreciate. Long
Also the HORMONAL GENERICS have big drawbacks:
So basically in a lot of cases, we are hearing that they are choosing to treat either SHPT or vitamin D insufficiency but not both. And while it would seem the rationale on the surface to stop treating vitamin D insufficiency in favor of treating only SHPT, it actually makes sense from the standpoint that hormonal products tend to exacerbate mineral metabolism disorders and this leads to clinicians having to try to titrate phosphate binders, nutritional and hormonal forms of vitamin D, in order to maintain control of the calcium, phosphorus and PTH, and it simply becomes too complicated for many clinicians to actually want to deal with.
So now in addition to asking about their current treatment practices, we want to share with them a product profile that represented what we believe could be the Rayaldee clinical study results. And in response, based on the Rayaldee product attributes that we presented to them and the way that they are currently practising, they expressed a high degree of interest in trying Rayaldee.